These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38385520)

  • 1. Early virological failure with cabotegravir/rilpivirine.
    Bailón L; Sábato S; Coll J; Santos JR; Miranda C; Puig T; D Avolio A; Paredes R; Moltó J; Negredo E
    J Antimicrob Chemother; 2024 May; 79(5):1193-1194. PubMed ID: 38385520
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine.
    Mazzitelli M; Avolio A; Carandina R; Parisi S; Wensing A; Cattelan A
    J Antimicrob Chemother; 2024 Aug; 79(8):2074-2076. PubMed ID: 38905150
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.
    van Welzen BJ; Van Lelyveld SFL; Ter Beest G; Gisolf JH; Geerlings SE; Prins JM; Van Twillert G; Van Nieuwkoop C; Van der Valk M; Burger D; Wensing AMJ
    Clin Infect Dis; 2024 Jul; 79(1):189-195. PubMed ID: 38207125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.
    Valin N; Lambert-Niclot S; Torres E; Meynard JL; Périllaud-Dubois C; Morand-Joubert L; Lacombe K
    Clin Infect Dis; 2024 Jul; 79(1):196-197. PubMed ID: 38513236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
    Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
    Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection.
    Med Lett Drugs Ther; 2021 May; 63(1625):81-83. PubMed ID: 34180282
    [No Abstract]   [Full Text] [Related]  

  • 8. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
    J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Odefsey--another NNRTI combination for HIV.
    Med Lett Drugs Ther; 2016 May; 58(1494):60-1. PubMed ID: 27148923
    [No Abstract]   [Full Text] [Related]  

  • 10. Concomitant use of anabolic androgen steroids and cabotegravir/rilpivirine leading to virological failure and development of two-class resistance.
    Burger D; Wttewaal E; Oosterhof P; Stalenhoef J
    AIDS; 2024 Sep; 38(11):1728-1729. PubMed ID: 39088831
    [No Abstract]   [Full Text] [Related]  

  • 11. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
    Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
    J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
    Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
    Ho S; Wong JG; Ng OT; Lee CC; Leo YS; Lye DCB; Wong CS
    AIDS Res Ther; 2020 May; 17(1):23. PubMed ID: 32438914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
    Gatechompol S; Avihingsanon A; Apornpong T; Han WM; Kerr SJ; Ruxrungtham K
    AIDS Res Ther; 2019 Apr; 16(1):7. PubMed ID: 30953533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
    Charpentier C; Storto A; Soulié C; Ferré VM; Wirden M; Joly V; Lambert-Niclot S; Palich R; Morand-Joubert L; Landman R; Lacombe K; Katlama C; Ghosn J; Marcelin AG; Calvez V; Descamps D
    J Antimicrob Chemother; 2021 Oct; 76(11):2983-2987. PubMed ID: 34015097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
    Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
    Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen.
    Todesco E; Surgers L; Marcelin AG; Calvez V; Meynard JL; Morand-Joubert L
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):e43-5. PubMed ID: 26818741
    [No Abstract]   [Full Text] [Related]  

  • 19. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
    D'Amico R; Cenoz Gomis S; Moodley R; Van Solingen-Ristea R; Baugh B; Van Landuyt E; Van Eygen V; Min S; Cutrell A; Foster C; Chilton D; Allard SD; Ruiter A
    HIV Med; 2023 Feb; 24(2):202-211. PubMed ID: 35945163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR
    Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.